Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Exicorilant · CORT-125281

Small molecule · Antagonist of glucocorticoid receptor (NR3C1) · developed by Corcept Therapeutics

Phase 1/2 Most advanced trial (none active)

CORT Developer

1 Registered trials

What is Exicorilant?

Exicorilant is an orally available selective glucocorticoid receptor antagonist. It competitively binds to glucocorticoid receptors to inhibit GR-mediated proliferative and anti-apoptotic gene expression. It is studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CORT-125281
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1)
Mechanism: Antagonist of glucocorticoid receptor (NR3C1)
Pathways: GR-mediated gene expression, cell proliferation, apoptosis
Therapy area: Oncology
Developer: Corcept Therapeutics (CORT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: GTB859B7K8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03437941	Phase 1/2	Metastatic Castration-Resistant Prostate Cancer	Terminated	CORT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-Resistant Prostate Cancer

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Miricorilant Phase 2 ORIC-101 Phase 1

More from Corcept Therapeutics

Relacorilant FDA approved CORT125236 Phase 1 CORT125329 Phase 1 Dazucorilant Phase 2 Miricorilant Phase 2 Nenocorilant Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CORT page.

Follow CORT, the company behind Exicorilant

See CORT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CORT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z